Showing results (161-170 of 194) with videos related to

Sort By:
Pageof 20
Journal of Viral Hepatitis|November 15, 2024
Preferences and Feasibility of Long-Acting Technologies for the Treatment of Hepatitis C Virus: A Survey of Patients in Diverse Low- and Middle-Income CountriesRenae Furl, Kimberly K Scarsi, Harlan Sayles, et al.
Nature Communications|June 10, 2022
Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulationSuyash Deodhar, Brady Sillman, Aditya N Bade, et al.
American Journal of Respiratory and Critical Care Medicine|April 2, 2024
High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical TrialKamunkhwala Gausi, Elisa H Ignatius, Veronique De Jager, et al.
Contemporary Clinical Trials|September 24, 2025
Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients: Study protocol for the PHOENIx phase 3 clinical trialMichelle A Kendall, Michael D Hughes, Soyeon Kim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 4, 2016
Evaluation of Xpert MTB/RIF Versus AFB Smear and Culture to Identify Pulmonary Tuberculosis in Patients With Suspected Tuberculosis From Low and Higher Prevalence SettingsAnne F Luetkemeyer, Cynthia Firnhaber, Michelle A Kendall, et al.
Ebiomedicine|July 19, 2021
Neuroinflammatory profiles regulated by the redox environment predicted cognitive dysfunction in people living with HIV: A cross-sectional studyRachel K Spooner, Brittany K Taylor, Cassandra M Moshfegh, et al.
The Pediatric Infectious Disease Journal|March 3, 2022
High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant TuberculosisSoyeon Kim, Xingye Wu, Michael D Hughes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 11, 2024
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for TuberculosisHuy X Ngo, Ava Y Xu, Gustavo E Velásquez, et al.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
American Journal of Respiratory and Critical Care Medicine|July 9, 2011
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmapPayam Nahid, Jussi Saukkonen, William R Mac Kenzie, et al.
Pageof 20